Joint research project aims at the improvement of companion diagnostics and therapy of tumor diseases
An international team from four EU countries plans to use an innovative concept to improve the use of companion diagnostics in disease and develop new approaches to therapy in the long term. The idea is to combine the use of nanomedicines and short half-life radionuclides for imaging purposes in the living organism.
First the nanomedicines, in the form of synthetic nanoparticles or antibodies, are introduced in the body where they actively or passively accumulate in certain organisms or cells. The second stage involves the delivery of a radioactive substance.
Where the substance encounters the nanoparticles, a rapid chemical reaction occurs and the two bind together, while the remainder of the substance is eliminated from the body. With the help of an imaging technique, it is now possible to precisely pinpoint where the nanoparticles are located, to what extent they have accumulated at the target site, and what effect they are having on the disease pathology. The EU is funding the project to the tune of EUR 6 million over the next five years.
Participating are physicians and clinicians from Copenhagen, chemists at TU Wien, and Johannes Gutenberg University Mainz (JGU), together with commercial partners from Austria and the Netherlands. The project was launched with the clear ambition of transferring the technology into clinical practice.
The research consortium aims at improving companion diagnostics and, at the same time, reducing exposure of patients to radioactivity to an absolute minimum. Companion diagnostics are tools in the form of medical devices that are used to assess medications in advance and can help determine which patients are likely to benefit from a treatment. For example, it is already possible to treat HER2-positive breast cancer using antibody therapy with relatively high therapeutic success rates.
However, only about 20 percent of all breast tumors are HER2-positive and the treatment is very expensive. It is thus advisable to first establish whether a patient is HER2-positive before initiating the therapy. Companion diagnostics can thus be used to determine if an individual patient is suitable for a specific form of therapy and would benefit from it or whether an alternative form of treatment should be preferred. In addition, the outcome of the therapy can be subsequently visualized. It is thus possible that the project may also contribute towards the future development of medicines that are more effective, more rapid, and less expensive.
"The system we are proposing would allow us to do far more than simply determine exactly where the nanoparticles are in the body," explained polymer chemist Dr. Matthias Barz of the Institute of Organic Chemistry at Mainz University, who is involved in the project. "There is the imaging factor that will allow us to see where our nanoparticles with their specific function are located in the body. And, eventually, it should at some point be possible to use our approach in radiotherapy – making it truly unique."
The two cooperation partners in Mainz, Dr. Matthias Barz and Professor Rudolf Zentel, are contributing their expertise in the production of microparticles of nanoparticles with specific functions. The European Union is making EUR 300,000 available over the next three years to fund their project.
Dr. Matthias Barz
Institute of Organic Chemistry
Johannes Gutenberg University Mainz (JGU)
55099 Mainz, GERMANY
phone: +49 6131 39-26256
fax: +49 6131 39-24778
http://www.uni-mainz.de/presse/19912_ENG_HTML.php - press release ;
http://www.ak-zentel.chemie.uni-mainz.de/eng/index.php - Zentel Group at the Institute of Organic Chemistry at Johannes Gutenberg University Mainz
Petra Giegerich | idw - Informationsdienst Wissenschaft
Designer cells: artificial enzyme can activate a gene switch
22.05.2018 | Universität Basel
Flow of cerebrospinal fluid regulates neural stem cell division
22.05.2018 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...
A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.
The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...
02.05.2018 | Event News
13.04.2018 | Event News
12.04.2018 | Event News
22.05.2018 | Life Sciences
22.05.2018 | Earth Sciences
22.05.2018 | Trade Fair News